Arrowhead Regional Medical Center
Colton, California, 92324, United States
Location status: Recruiting
Location contact
Kristina Nalbandyan, DO
CONTACT
Kristina Roloff, DO
CONTACT
NCT Number: NCT06543290
This is a double blinded randomized control trial involving administration of 2 grams prophylactic azithromycin in third trimester patients undergoing induction of labor at our institution to demonstrate reduction in maternal and neonatal infection.
Interested in participating?
Request Info18 year–45 year
Female
Interventional
Phase 1
Colton, California, 92324, United States
Location status: Recruiting
Kristina Nalbandyan, DO
CONTACT
Kristina Roloff, DO
CONTACT
Induction rates have more than tripled in the last quarter century, and even more in the past five years in light of evidence that the 39th week is the optimal gestational age for birth. Inductions are one of the most commonly performed medical procedures, and may span several days. One of the complications associated with induction include maternal infection, which includes chorioamnionitis, endometritis, pyelonephritis, neonatal infection, perineal and cesarean wound infections. There are many well-known risk factors for these infections that include longer duration of rupture of membrane, prolonged labor, nulliparity, internal monitoring, multiple vaginal examinations and several others. Well-established guidelines are available for treating infection once diagnosed, however the role of antibiotic prophylaxis to prevent infection in patients undergoing induction of labor is less clear. In this study, the investigators propose that administration of 2 grams oral azithromycin prior to the start of induction of labor will decrease rates of intrapartum and postpartum infections. Azithromycin is the ideal antibiotic to study in this trial since it is long acting, inexpensive, well tolerated, and has proven benefits in prior studies for prevention of obstetrical infection in cesarean deliveries and spontaneous labor. This is a double blinded randomized control trial involving administration of 2 grams prophylactic azithromycin in third trimester patients undergoing induction of labor at our institution to demonstrate reduction in maternal and neonatal infection. Decreasing rates of infection will improve both maternal and neonatal outcomes as well as decrease hospital length of stay and associated costs.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Azithromycin 2 grams to be administered prior to start of induction for those randomized to intervention group
4 magnesium oxide tablets prior to the start of induction for those randomized to placebo
Time frame: Delivery and 6 weeks postpartum
single oral dose of Azithromycin given prior to the start of induction of labor will decrease rates of composite infection
Time frame: Delivery and 6 weeks postpartum
single oral dose of azithromycin will also decrease rates of chorioamnionitis, endometritis, wound infection (both perineal and cesarean), neonatal infection and readmission rates, pyelonephritis, endomyometritis
Contact information is provided by the study sponsor or research team.
Kristina Nalbandyan, DO
CONTACT
Kristina Roloff, DO
CONTACT
Arrowhead Regional Medical Center
Other
Azithromycin to Prevent Chorioamnionitis in Women Undergoing Induction of Labor, a Randomized Control Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00006150
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn
Bethesda, Maryland, United States
View Trial DetailsNCT07220915
Agammaglobulinemia, Autoimmune Conditions
Scottsdale, Arizona, United States
View Trial DetailsNCT07607470
Bacterial Infections, Bacterial Infections and Mycoses
North Miami, Florida, United States
View Trial DetailsNCT00967785
Agammaglobulinemia, Agranulocytosis
Bethesda, Maryland, United States
View Trial Details